O besity and diabetes are both achieving epidemic proportions in the US. The shift from a hunter and gatherer food system to an easy access, calorie-dense diet combined with a sedentary life style without a change in our genetic code is part of the problem. All data indicate the best method of treatment for obesity is a change in lifestyle that includes a healthy diet and continuous exercise program. The same is true of the treatment of diabetes. All diabetes therapies work best when combined with a change in diet, exercise, and lifestyle. But not everyone is able or willing to make these changes. So, we turn to others to help solve the problem. This includes the expenditure of millions of dollars on various unproven products that appeal to our desire to lose weight, but they may not work and may even be unsafe. Some will turn to nonprescription or prescription medications that have shown to be marginally helpful and whose success is dependent on the combined use of the medication with a change in diet and exercise. Therefore, there are no magic bullets or easy ways to maintain permanent weight loss without making changes in a person's lifestyle and diet.
The latest tool to be considered in the treatment of obesity is OTC orlistat. GlaxoSmithKline has filed a new drug application with the Food and Drug Administration (FDA) to market a lower dose formulation of orlistat (Alli) as a nonprescription drug for the treatment of obesity.
The FDA Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Panels reviewed the submitted data in January 2006 and voted 11 to 3 that the product was safe and effective for sale as a nonprescription drug. If approved for OTC sale, orlistat 60 mg will become the first nonprescription product officially approved by the FDA for weight loss. This recommendation is not without critics. There is concern that not all patients will be able to fully understand the required labeling to determine if the drug is safe for their use. The briefing document prepared by the FDA indicated that only 35% of patients taking a medication for the treatment of their diabetes were able to determine if they were candidates for orlistat therapy, and 50% of those receiving an anticoagulant or immunosuppressant were able to make the same decision. At the time of the joint advisory panel meeting, Sidney Wolfe of the watchdog group Public Citizen was quoted as saying this was a "desperate attempt to revive this barely effective drug by an OTC switch." In April 2006, the same group filed a petition with the FDA asking it to withdraw orlistat from the market, because it increased the risk of aberrant crypt foci development in rats, which may be a precursor to colon cancer.
If the FDA does approve the OTC version of orlistat, its success will be very dependent on compliance with the recommended dosing regimen, a change in diet, and increased exercise. The greatest weight loss associated with the use of this product occurred in those patients whose diet diaries were monitored and in individuals whose initial body mass index was at least 28. The key will be whether patients are willing to make all these changes or will they consider this drug a fat blocker. If it is the latter, the OTC life of this drug will be very short lived. If the patient uses it as a fat blocker and continues to consume the same amount or more fat-containing foods they will pay a price later that day. Orlistat works by inhibiting gastrointestinal lipases, the enzymes necessary for the reduction in dietary fats, and subsequently decreasing the absorption of dietary fat. Its most common side effects are related to its effects in the gastrointestinal tract and the accumulation of fecal fats, abdominal discomfort, abdominal pain, increased frequency of defecation, steatorrhea, flatulence with oily discharge, and oily spotting. When the amount of fat in the diet is not decreased, the frequency of these side effects is increased. This effect has caused some health care professionals to refer to orlistat as the "Antabuse" for fat.
The long-term benefits of making this drug available as a nonprescription drug is unknown. The requested duration of therapy in the OTC labeling is only 6 months. No information is available regarding the longer use of the lowerdose orlistat or the success of subsequent therapies with the proposed nonprescription product. The prescription strength product (120 mg) is approved for chronic therapy, which is an important issue since people tended to gain weight after the discontinuation of any weight loss agent, including orlistat.
Making orlistat available without a prescription will make it available for more over-weight individuals, but it is not the magic solution for the obesity epidemic. Instead, it needs to be considered as a tool, just like all other weight loss products, and needs to be combined with changes in diet, lifestyle, and exercise patterns. If used correctly, it will help patients control their calorie intake and improve the imbalance between calorie ingestion and expenditure. The key question is whether the long-term benefits of this drug or any OTC drug is worth the monetary expenditure or would the person have benefited more from joining a supervised weight loss program like Weight Watchers or Jenny Craig? ■
